Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME: loxbutinib versus investigator-selected BTK inhibitor in relapsed or refractory mantle cell lymphoma
CTR20260122Phase 3Active
- Sponsor
- Lupeng Pharmaceutical
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HS-10561 in mantle cell lymphoma (MCL), sponsored by Lupeng Pharmaceutical. Started Feb 2026; status: active.
02
Drugs
HS-10561
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20260122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260122.